Medical Oncology Unit of Respiratory Tract and Sarcomas, New Drugs Development Division, European Institute of Oncology, Milan, Italy.
Crit Rev Oncol Hematol. 2012 Sep;83(3):432-43. doi: 10.1016/j.critrevonc.2011.12.005. Epub 2012 Feb 25.
Non-small cell lung cancer (NSCLC) remains the leading cause of cancer related mortality worldwide and despite some advances in therapy the overall prognosis remains disappointing. New therapeutic approaches like vaccination have been proposed and several clinical trials are ongoing. Many tumor antigens have been identified so far and specific tumor vaccines targeting these antigens have been developed. Even if the ideal setting for vaccine therapy might be the adjuvant one, vaccines seem to be potentially beneficial also in advanced disease and combination therapy could be a promising treatment option. In the advanced setting anti-MUC-1 vaccine (belagenpumatucel) and anti-TGF-β(2) vaccine (BPL-25) have entered in phase III trials as maintenance therapy after first line chemotherapy. In the adjuvant setting the most relevant and promising vaccines are directed against MAGE-A3 and PRAME, respectively. We will review the key points for effective active immunotherapies and combination therapies, giving an update on the most promising vaccines developed in NSCLC.
非小细胞肺癌（NSCLC）仍然是全球癌症相关死亡的主要原因，尽管在治疗方面取得了一些进展，但总体预后仍然令人失望。已经提出了新的治疗方法，如疫苗接种，并且正在进行几项临床试验。迄今为止，已经确定了许多肿瘤抗原，并且已经开发出针对这些抗原的特异性肿瘤疫苗。即使疫苗治疗的理想环境可能是辅助环境，但疫苗在晚期疾病中似乎也具有潜在的益处，联合治疗可能是一种有前途的治疗选择。在晚期环境中，抗 MUC-1 疫苗（belagenpumatucel）和抗 TGF-β(2)疫苗（BPL-25）已作为一线化疗后的维持治疗进入 III 期临床试验。在辅助环境中，最相关和最有前途的疫苗分别针对 MAGE-A3 和 PRAME。我们将回顾有效主动免疫治疗和联合治疗的要点，并更新 NSCLC 中开发的最有前途的疫苗。
